Identification of Adverse Drug Event-Related Japanese Articles: Natural Language Processing Analysis

JMIR Med Inform. 2020 Nov 27;8(11):e22661. doi: 10.2196/22661.

Abstract

Background: Medical articles covering adverse drug events (ADEs) are systematically reported by pharmaceutical companies for drug safety information purposes. Although policies governing reporting to regulatory bodies vary among countries and regions, all medical article reporting may be categorized as precision or recall based. Recall-based reporting, which is implemented in Japan, requires the reporting of any possible ADE. Therefore, recall-based reporting can introduce numerous false negatives or substantial amounts of noise, a problem that is difficult to address using limited manual labor.

Objective: Our aim was to develop an automated system that could identify ADE-related medical articles, support recall-based reporting, and alleviate manual labor in Japanese pharmaceutical companies.

Methods: Using medical articles as input, our system based on natural language processing applies document-level classification to extract articles containing ADEs (replacing manual labor in the first screening) and sentence-level classification to extract sentences within those articles that imply ADEs (thus supporting experts in the second screening). We used 509 Japanese medical articles annotated by a medical engineer to evaluate the performance of the proposed system.

Results: Document-level classification yielded an F1 of 0.903. Sentence-level classification yielded an F1 of 0.413. These were averages of fivefold cross-validations.

Conclusions: A simple automated system may alleviate the manual labor involved in screening drug safety-related medical articles in pharmaceutical companies. After improving the accuracy of the sentence-level classification by considering a wider context, we intend to apply this system toward real-world postmarketing surveillance.

Keywords: adverse drug events; medical informatics; natural language processing; pharmacovigilance.